Candel Therapeutics, Inc. – NASDAQ:CADL

Add to watchlist

$5.56

-3.30

-37.32%

Market closed

Open in about 16 hours

+45.41%

month

+45.41%

quarter

+538.13%

year

Market Cap	367.74M
Enterprise value	N/A

P/E	-2.14
EV/Sales	-300.77
EV/EBITDA	1.24
Price/Sales	424.60
Price/Book	0.82
PEG ratio	-0.03
EPS	-1.28

Revenue	N/A
EBITDA	-35.39M
Income	-37.36M
Revenue Q/Q	N/A
Revenue Y/Y	1809.67%

Profit margin	-25609.68%
Oper. margin	-56409.68%
Gross margin	33.33%
EBIT margin	-56409.68%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Candel Therapeutics, Inc. (NASDAQ:CADL): Profit margin
Jun 2023	0	-9.61M
Sep 2023	0	-8.43M
Dec 2023	1.77M	-11.09M	-624.72%
Mar 2024	0	-8.22M

Candel Therapeutics Financials Estimate

Q Y

Candel Therapeutics, Inc. (NASDAQ:CADL): Analyst Estimates
2025	4.34M	-26.89M	-618.62%
2026	92.5M	2.60M	2.82%

Analysts Price target
Financials & Ratios estimates

Candel Therapeutics, Inc. (NASDAQ:CADL): Earnings per share (EPS)
2023-11-09	-0.19	-0.29
2024-03-28	-0.16	-0.38

Candel Therapeutics, Inc. (NASDAQ:CADL): Debt to assets
Jun 2023	58708000	27.93M	47.59%
Sep 2023	50061000	27.03M	54.01%
Dec 2023	41702000	28.95M	69.44%
Mar 2024	31217000	25.23M	80.85%

Candel Therapeutics, Inc. (NASDAQ:CADL): Cash Flow
Jun 2023	-7.19M	-169K	0
Sep 2023	-8.80M	-103K	0
Dec 2023	-7.42M	-27K	-121K
Mar 2024	-8.43M	-7K	-1.25M

Candel Therapeutics alternative data

Candel Therapeutics, Inc. (NASDAQ:CADL): Employee count
Aug 2023	76
Sep 2023	76
Oct 2023	76
Nov 2023	76
Dec 2023	76
Jan 2024	76
Feb 2024	76
Mar 2024	76
Apr 2024	76
May 2024	42
Jun 2024	42
Jul 2024	42

Candel Therapeutics
Hedge Funds Holdings Q1 2023

9.64% -9.12%

of CADL is owned by hedge funds

13 -7

hedge funds hold CADL stock

2.77M -2.64M

shares is hold by hedge funds

CADL hedge funds holdings changes

Candel Therapeutics
Insider Trading

Candel Therapeutics, Inc. (NASDAQ:CADL): Insider trades (number of shares)
Period	Buy	Sel
Jul 2024	0	137123
Oct 2024	0	75414
Nov 2024	0	105255
Dec 2024	1250000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	16 Dec 2024	MANNING PAUL B director director	Common Stock	750,000	$6	$4,500,000
Purchase	16 Dec 2024	MANNING PAUL B director director	Common Stock	500,000	$6	$3,000,000
Sale	29 Nov 2024	TYAGARAJAN SESHU officer: Chief Technology Officer officer: Chief Technology Officer	Common Stock	20,392	$4.56	$92,906
Sale	29 Nov 2024	TAK PAUL PETER director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	48,847	$4.56	$222,547
Sale	29 Nov 2024	NICHOLS WILLIAM GARRETT officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	13,935	$4.56	$63,488
Sale	29 Nov 2024	BARONE FRANCESCA officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	22,081	$4.56	$100,601
Option	21 Nov 2024	TAK PAUL PETER director, officer: Chief Executive Officer director, officer: Chief Execut..	Stock Option (Right to Buy)	12,900	$1.55	$19,995
Option	21 Nov 2024	TAK PAUL PETER director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	12,900	$1.55	$19,995
Sale	15 Oct 2024	AGUILAR-CORDOVA ESTUARDO 10 percent owner 10 percent owner	CADL	10,412	$6.03	$62,784
Sale	14 Oct 2024	AGUILAR-CORDOVA ESTUARDO 10 percent owner 10 percent owner	CADL	15,000	$6.02	$90,300

CADL insider trading transactions

Candel Therapeutics
Executives

Insider	Age	Compensation
Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D. (1958) Founder, Chief Scientific Officer & Director	67	$740,150
Dr. Laura K. Aguilar (1965) Chief Medical Officer	60	$559,420
Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D. (1960) Pres, Chief Executive Officer & Director	65	$310,060
Mr. John J. Canepa (1956) Chief Financial Officer	69	$89,230

Candel Therapeutics
Latest News

Monday, 23 December 2024
14:41	2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases	proactiveinvestors.com
Thursday, 19 December 2024
15:16	Candel Therapeutics rides high on promising Phase 3 data, funding boost	proactiveinvestors.com
Monday, 16 December 2024
16:26	Candel Therapeutics raises $92M in public offering following prostate cancer trial success	proactiveinvestors.com
16:01	Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares	globenewswire.com
Friday, 13 December 2024
08:53	Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session	benzinga.com
08:48	Candel Therapeutics unveils $80M public offering	proactiveinvestors.com
Thursday, 12 December 2024
23:00	Candel Therapeutics Announces Pricing of Public Offering	globenewswire.com
16:51	Candel Therapeutics Announces $80 Million Proposed Public Offering	globenewswire.com
11:36	CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal	zacks.com
Wednesday, 11 December 2024
12:19	Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight	seekingalpha.com
10:55	Biotech Stock Hits 3-Year Highs on Trial Results	schaeffersresearch.com
09:19	Candel Therapeutics Stock Surges Over 100% - Here's Why	benzinga.com
09:17	Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug	investors.com
08:52	Candel Therapeutics reports positive Phase 3 results for CAN-2409 in localized prostate cancer	proactiveinvestors.com
07:09	Candel Therapeutics' cancer drug meets late-stage trial goals	reuters.com
07:00	Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival	globenewswire.com
Friday, 29 November 2024
10:31	Candel Therapeutics is pushing for a paradigm shift in cancer treatment	proactiveinvestors.com
Friday, 22 November 2024
10:01	Candel Therapeutics CEO: Putting patients first is the key to reframing cancer treatment	proactiveinvestors.com
Thursday, 14 November 2024
09:44	Candel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps up	proactiveinvestors.com
Saturday, 9 November 2024
10:13	Candel Therapeutics' CAN-3110 offers new hope for melanoma treatment – ICYMI	proactiveinvestors.com
Tuesday, 5 November 2024
10:03	Candel Therapeutics eyes new indication for CAN-3110 in melanoma following positive preclinical results	proactiveinvestors.com
09:00	Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma	globenewswire.com
Friday, 1 November 2024
12:40	Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think	seekingalpha.com
Friday, 4 October 2024
09:00	Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting	globenewswire.com
Monday, 29 July 2024
15:32	3 Biotech Names With Potential Catalysts By Year End	seekingalpha.com
Tuesday, 11 June 2024
08:00	Candel Therapeutics to Join Russell 3000® Index	globenewswire.com
Thursday, 30 May 2024
08:00	FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma	globenewswire.com
Tuesday, 28 May 2024
12:11	Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why	zacks.com
Friday, 24 May 2024
12:46	Candel (CADL) Reports Upbeat Data From Lung Cancer Study	zacks.com
Thursday, 23 May 2024
17:00	Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting	globenewswire.com

Ideas & Opinions

Seeking Alpha 3 Jan 2025

Best-Performing Stocks Of 2024
Seeking Alpha 11 Dec 2024

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight
Seeking Alpha 1 Jul 2024

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
Seeking Alpha 15 Apr 2024

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Seeking Alpha 21 Oct 2021

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Seeking Alpha 31 Jul 2021

U.S. IPO Weekly Recap: Biotechs Pop And Robinhood Flops In A Record 20 IPO Week

Frequently Asked Questions (FAQ)

What's the price of Candel Therapeutics stock today?

One share of Candel Therapeutics stock can currently be purchased for approximately $5.56.
When is Candel Therapeutics's next earnings date?

Unfortunately, Candel Therapeutics's (CADL) next earnings date is currently unknown.
Does Candel Therapeutics pay dividends?

No, Candel Therapeutics does not pay dividends.
How much money does Candel Therapeutics make?

Candel Therapeutics has a market capitalization of 367.74M. Candel Therapeutics made a loss 37.94M US dollars in net income (profit) last year or -$0.38 on an earnings per share basis.
What is Candel Therapeutics's stock symbol?

Candel Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CADL".
What is Candel Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Candel Therapeutics?

Shares of Candel Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Candel Therapeutics's key executives?
Candel Therapeutics's management team includes the following people:
- Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D. Founder, Chief Scientific Officer & Director(age: 67, pay: $740,150)
- Dr. Laura K. Aguilar Chief Medical Officer(age: 60, pay: $559,420)
- Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D. Pres, Chief Executive Officer & Director(age: 65, pay: $310,060)
- Mr. John J. Canepa Chief Financial Officer(age: 69, pay: $89,230)
Is Candel Therapeutics founder-led company?

Yes, Candel Therapeutics is a company led by its founder Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D..
How many employees does Candel Therapeutics have?

As Jul 2024, Candel Therapeutics employs 42 workers, which is 45% less then previous quarter.
When Candel Therapeutics went public?

Candel Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 27 Jul 2021.
What is Candel Therapeutics's official website?

The official website for Candel Therapeutics is candeltx.com.
Where are Candel Therapeutics's headquarters?

Candel Therapeutics is headquartered at 117 Kendrick Street, Needham, MA.
How can i contact Candel Therapeutics?

Candel Therapeutics's mailing address is 117 Kendrick Street, Needham, MA and company can be reached via phone at +61 79165445.

Candel Therapeutics, Inc.

candeltx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

+61 79165445

117 Kendrick Street
Needham, MA 02494

CIK: 0001841387
ISIN: US1374041093
CUSIP: 137404109